Lessons learned from randomized-controlled studies in patients with Tourette syndrome and chronic tic disorders

Klages, C S, Ringlstetter, R 2, Häckl, S 2, Großenhagen, A 2 and Müller-Vahl, K 1

1 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany
2 Institute of Biostatistics, Hannover Medical School, Hannover, Germany

BACKGROUND

ONLINE-TICS (1) and CANNA-TICS (2) are multi-centered randomized controlled trials (RCTs) investigating efficacy of internet-delivered Comprehensive Behavioral Intervention for Tics (CIBIT) and the cannaboid nabiximols, respectively, in patients with Tourette syndrome (TS). Both trials were designed similarly, particularly related to population and psychometric measurements. Both studies did not reach their primary endpoint but showed strong trends towards significance.

OBJECTIVE

A joint analysis of the two trials using individual patient data to enable more detailed insight into differences in patient populations and different treatments for patients with TS and chronic tic disorders.

METHODOLOGY

Descriptive analyses of common baseline variables were performed to assess similarities and differences between trial populations using two-sample t-test. Furthermore, the Yale Global Tic Severity Scale-Total Tic Score (YGTTSS-TTS) was compared over the course of the trials. Prognostic factors for study participation were identified exploratory in multivariable logistic regression. Although in both RCTs, the YGTTSS-TTS had been used to assess the primary endpoint, different approaches in analysis were applied. While in ONLINE-TICS analysis of the YGTTSS-TTS was applied continuously, in CANNA-TICS a dichotomous responder criterion was defined (3).

RESULTS

CANNA-TICS trial enrolled n = 97 patients, ONLINE-TICS trial enrolled n = 161 patients. We excluded all patients that participated in both trials (n = 20). Patient populations differed substantially at baseline with respect to tic severity according to the YGTTSS-TTS:

- ONLINE-TICS: mean 24.4 (SD±8.1) versus CANNA-TICS: mean 28.8 (SD±18.7), p < .0001

Only descriptive analyses on the course of the YGTTSS-TTS were possible. Even though the YGTTSS-TTS at baseline differed between trials, the change of the YGTTSS-TTS over the course of the trials was quite similar (Figure 1). We identified the following baseline variables as factors favoring participation in the CANNA-TICS study:

- a YGTTSS-TTS ≥ 28 (OR 2.2, 95%-CI [1.3; 3.9], p = 0.0044)
- housing situation “living alone” (OR 2.0, 95%-CI [1.1; 3.6], p = 0.0179)
- presence of psychiatric comorbidities (OR 1.9, 95%-CI [1.1; 3.2], p = 0.0253)

Figure 1: Change of the YGTTSS-TTS over the course of the trials (presented are all patients with available data).

CONCLUSION

We identified substantial differences in the CANNA-TICS population compared to the ONLINE-TICS population, yet the same study centers were involved in both studies, nearly the same psychometric measurements were used and similar in- and exclusion criteria were applied.

- This may indicate selection bias and allows for a discussion about patients’ preconceptions (e.g. prejudices against medical cannabis) in different treatments for TS and tic disorders.
- A joint evaluation of different RCTs may provide valuable new insights into different kinds of treatment for patients with TS and other chronic tic disorders.

REFERENCES